Search clinical trials for: CD70-targeting CAR-T cells

Total 2352 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Recurrent Mantle Cell Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Refractory Chronic Lymphocytic Leukemia | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Acute Lymphoblastic Leukemia | Metastatic Triple-Negative... and other conditions

United States
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
University of Pennsylvania

Completed

cMet CAR RNA T Cells Targeting Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer

United States
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...

Unknown

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (MeCAR)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...

China
Shanghai Tongji Hospital, Tongji University School...

Unknown

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Lymphoma | Leukemia

China
Sinobioway Cell Therapy Co., Ltd.

Unknown

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Lymphoma

China
Sinobioway Cell Therapy Co., Ltd.
The First Affiliated Hospital of Anhui Medical University

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (EECBL)

Lymphoma

China
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
The Second Hospital of Nanjing Medical University

Unknown

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Nasopharyngeal Neoplasms

China
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast Cancer | Pancreatic Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma | Other Solid Tumors

United States
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia | Refractory | Relapsed

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

B Cell Leukemia

China
Beijing Boren Hospital

Recruiting

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)

Hodgkin's Lymphoma | Non-Hodgkin Lymphoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sir Run Run Shaw Hospital

Completed

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Multiple Myeloma

China
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
CytoMed Therapeutics Pte Ltd

Unknown

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast Cancer

Malaysia
Peking University
Peking University Cancer Hospital & Institute

Recruiting

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

B Cell Non-Hodgkin's Lymphoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
The Third Affiliated Hospital of Guangzhou Medical...

Unknown

Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours

Solid Tumours

China
Molecular Partners AG

Recruiting

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Leukemia | Acute | Relapsed | Myeloid

Netherlands, France, Lithuania, Switzerland
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
XuYan

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Belarusian Research Center for Pediatric Oncology...

Recruiting

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

B-cell Acute Lymphoblastic Leukemia | Lymphoblastic B-Cell Lymphoma

Belarus
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Recruiting

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Memorial Sloan Kettering Cancer Center
Takeda

Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Burkitt's Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Primary CNS Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Fudan University
Guangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu，Principal Investigator...

Recruiting

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Xuzhou Medical University
Yake Biotechnology Ltd.

Recruiting

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma (CAR-T)

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: CD70-targeting CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations